Fig. 6From: Small Molecule KRAS Agonist for Mutant KRAS Cancer TherapyToxicity of KRA-533 in vivo. (a), (b) and (c) Body weight, blood analysis and H&E histology of various organs from mice bearing A549 xenografts after treatment with various doses of KRA-533 for 28 daysBack to article page